LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS) today announced that the underwriters participating in its initial public offering of common stock have exercised in full their option to purchase an additional 900,000 shares from the company at the public offering price of $18.00 per share, less underwriting discounts and commissions. Total net proceeds to Glaukos from the offering, including proceeds from the option exercise, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.3 million. The closing of the option exercise is expected to occur concurrent with the closing of the offering on June 30, 2015, subject to customary closing conditions.
Glaukos’s common stock began trading on the New York Stock Exchange on June 25, 2015 under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and has been declared effective. The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: (866) 803-9204; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Glaukos
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry's first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150625006436/en/
Source: Glaukos Corporation